Current HCV direct acting antiviral (DAA) regimens are highly efficacious; including in populations previously recognized to have poor responses to interferon-based therapies (e.g. HIV co-infection, cirrhosis etc.). However, as DAAs are used in a greater number of patients in clinical practice, scenarios which have not been adequately addressed in clinical trials, or are impractical to study, will invariably arise. The approach to management of HCV treatment interruptions of varying durations at different times during therapy and re-treatment for multiple DAA regimens failures are examples of such scenarios.
In this interactive session, cases will be used to highlight clinical conundrums focusing on:
- Determination or HCV relapse versus reinfection
- Multiple DAA regimens failure retreatment
- Approach to treatment interruptions during DAA therapy
While FDA approved options for retreatment exist for initial DAA regimen failure, robust data are lacking for patients failing multiple DAA regimens and retreatment approaches are not standardized. Inferences from studies in other HCV scenarios can provide insight into reasonable re-treatment approaches which generally rely on extension of therapy with addition of other drug classes and ribavirin when possible. In situations where no data exists- such as evidence based approaches for dealing with treatment interruptions, expert opinion and audience input will be used to offer management options.